DVA Stock Analysis — DaVita Inc.
Sector: Healthcare
AI Verdict
DaVita trades at 15.5x forward earnings with 38.1% EPS growth expected, which is cheap for the growth if its clinic network moat holds, but the overbought RSI signals elevated near-term risk.
Competitive Moat
DaVita operates a vast network of dialysis clinics, benefiting from high barriers to entry due to regulatory complexity and the need for scale in negotiating with payers. Its entrenched relationships with insurers and hospitals create switching costs that help defend its market share.
Summary
DaVita's stock is running hot after a 62.66% one-year return and a forward P/E drop to 15.5x on 38.1% expected EPS growth.
Where It Stands
With an RSI of 79.3, DaVita is technically overbought, but its forward P/E of 15.5x is below the healthcare sector median of 22x while earnings are expected to jump 38.1% next year.
Key Metrics
- RSI: 79.3 — Overbought
- Trailing P/E: 21.4x
- Forward P/E: 15.5x
- PEG Ratio: 0.58
- Earnings Growth: +0.4%
- Revenue Growth: +0.1%
- Market Cap: $14.8B
- 1-Year Return: 62.66%
- 52-Week High: $239.64
- 52-Week Low: $101.00
Analyst Consensus
6 Buy · 6 Hold · 1 Sell (13 analysts)
Bull Case
You're paying just 15.5x next year's earnings for a company expected to grow EPS by 38.1%, which is cheap for the growth on offer given its scale-driven moat.
Bear Case
At an RSI of 79.3, the stock is overbought and could see a sharp pullback if sentiment cools, risking a drop toward sector-average multiples and erasing some of the 62.66% one-year gain.
Catalyst to Watch
Watch for quarterly earnings surprises or regulatory changes in dialysis reimbursement rates, as either could quickly change the forward growth narrative.